Investigating the therapeutic effect of octreotide in patients with pulmonary contusion

Investigating the therapeutic effect of octreotide on respiration, altretion prosess of SPO2, inflammation, and coagulation parameters of patients with lung contusion.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201013049017N5

Enrollment

Registered

2025-10-16

Start date

2025-10-16

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung contusion. Contusion of lung

Interventions

Intervention 1: Intervention group: In the experimental group, in addition to receiving routine medications—including general analgesics such as acetaminophen, oxygen therapy via nasal cannula (if nee

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patient satisfaction Weight 40 to 90 kg, age 20 to 50 years. A patient with a diagnosis of pulmonary contusion and non-intubation, at the beginning of admission to the hospital. PaO2/FiO2 Ratio between 100 and 300 and PCS less than 7. Not participating in another clinical trial study

Exclusion criteria

Exclusion criteria: Bradycardia and bradyarrhythmia Prescribing medications other than routine medications Allergic reaction to octreotide Withdrawal of the patient or patient companion during the study Suffering from various infections Fever over 39 degrees Celsius

Design outcomes

Primary

Measure	Time frame
Changes of blood oxygen saturation (SpO2) in each day of inpatient. Timepoint: At the beginning of the patient's admission and in each days up to discharge of patient. According to before studies, 32 patients is required for each groups or 64 patients is required for total sample size of study to evaluating primary variables. Method of measurement: Measured using a pulse oximeter.;Coagulation factors: Partial Thromboplastin Time (PTT), Prothrombin Time (PT), D Dimer. Timepoint: At the time of admission, at 5th day. According to before studies, 32 patients is required for each groups or 64 patients is required for total sample size of study to evaluating primary variables. Method of measurement: By automated blood coagulation analyzer and standard kits associated with this device.;Inflammatory factors: transferrin and C- Reactive Peptide. Timepoint: At the time of admission, at 5th day. According to before studies, 32 patients is required for each groups or 64 patients is required for total sample size of study to evaluating primary variables. Method of measurement: By Mindray BS-2000 device and standard kits related to this device.;Pulmonary parameters: The ratio of arterial oxygen partial pressure to the fraction of inspired oxygen.PaO2/FiO2 Ratio and deference of Alveolar and arterial of O2 (PA-aO2). Timepoint: At the beginning of the patient's admission (before the start of the intervention), and on days 1, 5, and 10 (end ?of the study period). According to before studies, 32 patients is required for each groups or 64 patients is required for total sample size of study to evaluating primary variables. Method of measurement: Measured through arterial blood gas (ABG) tests and flowmeter of inspiration of O2.	—

Measure

Time frame

Changes of blood oxygen saturation (SpO2) in each day of inpatient. Timepoint: At the beginning of the patient's admission and in each days up to discharge of patient. According to before studies, 32 patients is required for each groups or 64 patients is required for total sample size of study to evaluating primary variables. Method of measurement: Measured using a pulse oximeter.;Coagulation factors: Partial Thromboplastin Time (PTT), Prothrombin Time (PT), D Dimer. Timepoint: At the time of admission, at 5th day. According to before studies, 32 patients is required for each groups or 64 patients is required for total sample size of study to evaluating primary variables. Method of measurement: By automated blood coagulation analyzer and standard kits associated with this device.;Inflammatory factors: transferrin and C- Reactive Peptide. Timepoint: At the time of admission, at 5th day. According to before studies, 32 patients is required for each groups or 64 patients is required for total sample size of study to evaluating primary variables. Method of measurement: By Mindray BS-2000 device and standard kits related to this device.;Pulmonary parameters: The ratio of arterial oxygen partial pressure to the fraction of inspired oxygen.PaO2/FiO2 Ratio and deference of Alveolar and arterial of O2 (PA-aO2). Timepoint: At the beginning of the patient's admission (before the start of the intervention), and on days 1, 5, and 10 (end ?of the study period). According to before studies, 32 patients is required for each groups or 64 patients is required for total sample size of study to evaluating primary variables. Method of measurement: Measured through arterial blood gas (ABG) tests and flowmeter of inspiration of O2.

—

Secondary

Measure	Time frame
The duration of the day it took for the SPO2 (with nasal oxygen and a flow rate of 2 liters per minute or FIO2 less than 30%) to increase to above 92%. Timepoint: In each morning. Method of measurement: Pulse oximeter.;Length of stay at hospital. Timepoint: The time interval between the time of admission and the time of discharge of the patient. Method of measurement: Admission and discharge times recorded in the patient's file.;Hemodynamic parameters : blood pressure, Heart rate, Pulse Pressure. Timepoint: In each morning. Method of measurement: with monitoring device.;Cell Blood Count. Timepoint: At the time of admission, 5th day, end day. Method of measurement: With laboratory device of Mindray BC 6800 automated hematology analyzer focusing flow-DC ?method.;The number of breaths per minute in patients with pulmonary contusion. Respiratory Rate. Timepoint: It will be performed at the beginning of the patient's admission (before the start of the intervention) and every ?morning on days 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 after the start of the intervention. According to the literature 64, ?patients is required, which will be found within a period of approximately 10 months due to the prevalence of ?pulmonary contusion and inclusion criteria?.?. Method of measurement: Counted manually or monitored using a device?.?.	—

Measure

Time frame

The duration of the day it took for the SPO2 (with nasal oxygen and a flow rate of 2 liters per minute or FIO2 less than 30%) to increase to above 92%. Timepoint: In each morning. Method of measurement: Pulse oximeter.;Length of stay at hospital. Timepoint: The time interval between the time of admission and the time of discharge of the patient. Method of measurement: Admission and discharge times recorded in the patient's file.;Hemodynamic parameters : blood pressure, Heart rate, Pulse Pressure. Timepoint: In each morning. Method of measurement: with monitoring device.;Cell Blood Count. Timepoint: At the time of admission, 5th day, end day. Method of measurement: With laboratory device of Mindray BC 6800 automated hematology analyzer focusing flow-DC ?method.;The number of breaths per minute in patients with pulmonary contusion. Respiratory Rate. Timepoint: It will be performed at the beginning of the patient's admission (before the start of the intervention) and every ?morning on days 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 after the start of the intervention. According to the literature 64, ?patients is required, which will be found within a period of approximately 10 months due to the prevalence of ?pulmonary contusion and inclusion criteria?.?. Method of measurement: Counted manually or monitored using a device?.?.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamid Talebzadeh

Esfahan University of Medical Sciences

talebzadeh.h@med.mui.ac.ir+98 31 3620 1995

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026